Switch theme
Sign up to access all valuation multiples
Arzneiwerk AG VIDA is active in the pharmaceutical industry. The Pharma segment combines pharmaceutical supply with a focus on digitalization and process optimization along the pharmaceutical value chains and the management of large data volumes in the pharmaceutical industry. The company focuses on the growth area of specialty pharma in Germany and Europe which usually includes high-priced drugs for chronic, complex, or rare diseases such as oncology, neurology, autoimmune diseases, ophthalmology, hemophilia, and infectious diseases.
1983
39
LTM Revenue n/a
LTM EBITDA n/a
$13.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Arzneiwerk VIDA has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Arzneiwerk VIDA achieved revenue of $1.8M and an EBITDA of -$2.0M.
Arzneiwerk VIDA expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Arzneiwerk VIDA valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.8M | n/a | XXX | XXX | XXX |
| Gross Profit | $2.2M | $2.0M | XXX | XXX | XXX |
| Gross Margin | 121% | NaN% | XXX | XXX | XXX |
| EBITDA | -$2.0M | n/a | XXX | XXX | XXX |
| EBITDA Margin | -110% | NaN% | XXX | XXX | XXX |
| Net Profit | $0.3M | -$1.8M | XXX | XXX | XXX |
| Net Margin | 16% | NaN% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Arzneiwerk VIDA's stock price is EUR 0 (or $0).
Arzneiwerk VIDA has current market cap of EUR 2.2M (or $2.4M), and EV of EUR 12.8M (or $13.7M).
See Arzneiwerk VIDA trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13.7M | $2.4M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Arzneiwerk VIDA has market cap of $2.4M and EV of $13.7M.
Arzneiwerk VIDA's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Arzneiwerk VIDA's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Arzneiwerk VIDA and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $13.7M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpArzneiwerk VIDA's NTM/LTM revenue growth is n/a
Arzneiwerk VIDA's revenue per employee for the last fiscal year averaged $46K, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Arzneiwerk VIDA's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Arzneiwerk VIDA's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Arzneiwerk VIDA and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $46K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 195% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| TKH Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Elsight | XXX | XXX | XXX | XXX | XXX | XXX |
| Intracom Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| Thaicom | XXX | XXX | XXX | XXX | XXX | XXX |
| HFCL | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Arzneiwerk VIDA acquired XXX companies to date.
Last acquisition by Arzneiwerk VIDA was XXXXXXXX, XXXXX XXXXX XXXXXX . Arzneiwerk VIDA acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Arzneiwerk VIDA founded? | Arzneiwerk VIDA was founded in 1983. |
| Where is Arzneiwerk VIDA headquartered? | Arzneiwerk VIDA is headquartered in Germany. |
| How many employees does Arzneiwerk VIDA have? | As of today, Arzneiwerk VIDA has 39 employees. |
| Is Arzneiwerk VIDA publicy listed? | Yes, Arzneiwerk VIDA is a public company listed on FRA. |
| What is the stock symbol of Arzneiwerk VIDA? | Arzneiwerk VIDA trades under TLIK ticker. |
| When did Arzneiwerk VIDA go public? | Arzneiwerk VIDA went public in 1998. |
| Who are competitors of Arzneiwerk VIDA? | Similar companies to Arzneiwerk VIDA include e.g. TKH Group, Elsight, Intracom Holdings, Thaicom. |
| What is the current market cap of Arzneiwerk VIDA? | Arzneiwerk VIDA's current market cap is $2.4M |
| Is Arzneiwerk VIDA profitable? | Yes, Arzneiwerk VIDA is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
